Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Ding Q, Markesbery WR, Chen Q, Li F, Keller JN. Ribosome dysfunction is an early event in Alzheimer's disease. J Neurosci. 2005 Oct 5;25(40):9171-5. PubMed Abstract

  
Comments on Paper and Primary News
  Primary News: Making a Vaccine Work: Profiles, Protein Synthesis, and Synapses

Comment by:  Paul Coleman, ARF Advisor
Submitted 23 October 2005  |  Permalink Posted 24 October 2005

The protection of synapses is, indeed, a vital component in the early treatment of AD. However, evidence suggests that the presence or absence of synapses is far from the whole synaptic story. We have shown that reduced expression of selected transcripts and proteins involved in trafficking of synaptic vesicles is found in postmortem AD brain even when other markers of synaptic structure may be unaffected (Yao et al., 2003). One of the gene products we found to be most reduced in AD was dynamin 1, a molecule critical in synaptic vesicle trafficking. More recently, Adriana Ferreira and her co-workers demonstrated that Aβ reduced the expression of dynamin 1 in hippocampal neurons (Kelly et al., 2005). These two papers suggest that markers of synaptic function would be a more sensitive marker of early synaptic deficits than markers related to only the presence or absence of synapses.

References:
Yao PJ. Zhu M. Pyun EI. Brooks AI. Therianos S. Meyers VE. Coleman PD. Defects in expression of genes related to synaptic vesicle trafficking in frontal cortex of Alzheimer's disease. Neurobiol Dis. 2003 Mar;12(2):97-109. Abstract

Kelly BL, Vassar R, Ferreira A. Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease. J Biol Chem. 2005 Sep 9;280(36):31746-53. Epub 2005 Jul 7. Abstract

View all comments by Paul Coleman

  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:

For Western blotting antibodies against FK506-binding protein-rapamycin-associated protein (FRAP), phosphorylated p70 S6 kinase, phosphorylated eukaryotic initiation factor 2 (eIF2a), and phosphorylated double-stranded RNA-activated protein kinase (PKR) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling Technology (Beverly, MA).

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad